ХРОНИЧЕСКАЯ БОЛЬ: МЕДИКО-БИОЛОГИЧЕСКИЕ И СОЦИАЛЬНО-ЭКОНОМИЧЕСКИЕ АСПЕКТЫ

In this article the role of neurobiological, psychological and social factors in pathogenesis of chronic pain is analyzed. The chronic pain is considered not as a symptom of damage of tissue and as independent illness due to non-adequate neuroplasticity of systems involved into regulation of pain sensitivity. The major role in development and maintenance of chronic pain is devoted to the primary genetically determined and/or secondary disturbance of interaction between nociceptive and antinociceptive systems at various levels - from peripheral neuron to central structures – that provides pain perception and painful behaviour development. В работе анализируется значение нейробиологических, психологических и социальных факторов в патогенезе хронической боли. Хроническая боль рассматривается не как симптом повреждения тканей, а как самостоятельная болезнь, возникающая вследствие неоптимальной нейропластической реорганизации систем, осуществляющих регуляцию болевой чувствительности. Важнейшая роль в развитии и поддержании хронической боли отводится первичному генетически детерминированному и/или вторичному нарушению взаимодействия ноцицептивной и антиноцицептивной систем на различных уровнях — от периферического нейрона до центральных структур, обеспечивающих восприятие боли и формирование болевого поведения.

Russian multicenter study of fixed combination of diclofenac and orphenadrine its efficacy and tolerance of in acute non-specific pain and radiculopathy relief

The article presents the result NEODOLEX study. It was Russian multicenter statistical efficacy and tolerability observation of Neodolpasse which is a fixed combination of the non-steroidal anti-inflammatory drug (NSAID) diclofennac (75 mg) and the muscle relaxant orphenadrine (30 mg) for acute nonspecific back pain and radiculopathy treatment. The study has showed Neodolpasse infusions lead to the fast (after 24 hours) and significant pain regression (more than 50%) in 94% of patients. Depending on the frequency of Neodolpasse use, additional application of other analgesics was required in 21—35% of patients with acute nonspecific back pain and 11—17% of patients with radiculopathy. © 2022, Media Sphera Publishing Group. All rights reserved